Rockwell Medical Q1 revenue $19.7M (+22.4% YoY); net loss narrows to $0.10/share

ROCKWELL MEDICAL, INC.

2023-Q1 EPS reported -$0.10 revenue$19,668,000

Revenue of $19.7M, up 22.4% YoY; gross profit of $2.6M vs gross loss of $0.8M in Q1 2022.
Net loss of $1.75M ($0.10/share) vs $7.2M ($0.84) a year ago; operating loss improved to $1.4M.
Reiterates 2023 guidance: revenue $78-82M, gross profit $7-9M, targeting profitability in 2024.
Signed long-term supply agreements with largest U.S. non-profit dialysis provider and Concerto Renal Services.
Assumed full commercial responsibility for Baxter customers; cash stood at $16.8M at quarter-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ROCKWELL MEDICAL, INC. reported the three months ended March 31, 2023 results: revenue $19.7 million, net income $1.75 million, EPS $0.10* per share. Guidance reaffirmed.

Period: the three months ended March 31, 2023
Revenue: $19.7 million
Net income: $1.75 million
EPS: $0.10* per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

in such a filing. --- EX-99.1 (EX-99.1) --- Rockwell Medical Announces First Quarter 2023 Results • Achieved fourth consecutive quarter of revenue growth with new high of $19.7 million, representing a 22.4% increase over the same period in 2022 • Achieved $2.6 million in gross profit, representing a 425% increase over the same period in 2022 • Continued to

View on SEC.gov

Browse all earnings releases →

ROCKWELL MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-017984

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.